Tirzepatide
Tirzepatide (Mounjaro, Zepbound): approved uses, how it differs from semaglutide, label warnings, and how compounded vials are measured.
FDA-approved · Evidence grade A · Reviewed
Tirzepatide (Mounjaro, Zepbound). GIP and GLP-1 receptor agonist.
AFDA-approved. Evidence grade A: approved, large human trials.
What is Tirzepatide?
Tirzepatide acts on two hormone receptors, GIP and GLP-1. It is the only approved drug that targets both.
Is Tirzepatide FDA-approved?
Approved as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management. Zepbound was also approved in 2024 for obstructive sleep apnea in people with obesity.
What does the evidence show for Tirzepatide?
Large human trials across diabetes, weight management and sleep apnea.
What are the known risks of Tirzepatide?
The label carries a boxed warning about thyroid C-cell tumors, based on rodent studies. It is not known whether the same happens in people. The most common side effects are nausea, vomiting, diarrhea, constipation and stomach pain. Labels for this class also warn about pancreatitis.
How is Tirzepatide measured?
Brand-name pens are pre-measured, so there is nothing to calculate. If a pharmacy dispenses a vial labeled in mg per mL, the Pre-mixed mode converts a prescribed dose into syringe units. FDA declared the tirzepatide shortage over in December 2024.
Sources: Managed Healthcare Executive: GLP-1 pills; Prime Therapeutics: GLP-1 pipeline update, August 2026; Polsinelli: FDA compounded GLP-1 policy. This profile does not recommend any dose or use.
For research and educational use. Not medical advice. Regulatory status changes, so confirm the current position with FDA or a licensed professional.